RTA
10 mg
€ 83,00
per vialAvailable10 mg laboratory research material. Clearly identified and supplied for legitimate analytical use only.
Vial sets
1 vial · € 83,00 total · + € 4,99 PostNL shipping per order
- Reference
- MVP / 001
- Strength
- 10 mg
- Availability
- Available
- Handling
- Store cool and dry, away from light. Laboratory handling only.
- Shipping
- PostNL within the Netherlands, € 4,99 per order
Specification
For research only. Not for human use.
Key research areas
- Triple-receptor signalling (GIP, GLP-1, glucagon)
- Glucose regulation and insulin response
- Energy expenditure and metabolic rate
- Appetite and satiety pathways
- Body-weight regulation in clinical models
Potential benefits observed in research
- Phase 2 trial participants showed marked body-weight reduction versus placebo.
- Improved glycaemic markers reported in controlled metabolic studies.
- Simultaneous activation of three receptors offers a broader metabolic profile than single-pathway compounds.
- Increased energy expenditure observed alongside reduced caloric intake in study settings.
Reported observations from published studies under controlled conditions. They do not establish the safety, quality or performance of this research material.
Research documentation
RTA — 10 mg
Retatrutide is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. This combined receptor profile makes it scientifically distinctive within research on metabolic regulation. Researchers are investigating how coordinated signalling through these pathways influences appetite, glucose control and energy balance. Human clinical studies have examined body-weight changes and metabolic outcomes, including a randomized phase 2 trial in adults with obesity.
Key Research Areas
- Metabolic signalling
- glucose regulation
- energy balance
- body-weight regulation
These findings relate to the investigational drug and controlled study conditions; they do not establish the safety or performance of an independently supplied research vial. MVP RTA is presented as a research material and is not an approved medicine or a substitute for the clinical-trial product. Human trial; development status.
For research purposes only. Not for human consumption or therapeutic use.
